Bismuth subcitrate

Generic Medicine Info
Indications and Dosage
Benign gastric and duodenal ulceration
Adult: 240 mg bid or 120 mg 4 times daily for 4 wk, may be extended to 8 wk if needed. May also be repeated after one mth of drug-free interval.

H. pylori infection
Adult: 120 mg 4 times daily in combination with other drugs given for 2 wk.
Renal Impairment
Moderate-severe impairment: Avoid use.
Moderate-severe renal insufficiency. Pregnancy, child <14 yr.
Special Precautions
Lactation. Monitor renal function regularly.
Adverse Reactions
Darkening of tongue or stools. Nausea, vomiting, bone and joint toxicity.
Potentially Fatal: Possibility of bismuth poisoning and fatal encephalopathy in patients with renal impairment or if given over prolonged periods. Renal failure and liver damage.
Overdosage may lead to serious adverse effects such as renal failure, encephalopathy and neurotoxicity. May consider gastric lavage, purgation and hydration. Chelating agents may be useful.
Drug Interactions
Food, milk, antacids, tetracyclines and H2-receptor antagonists reduce activity of drug.
Mechanism of Action: Bismuth subcitrate is used in the management of gastric and duodenal ulcers and specifically against H.pylori as part of a triple drug regimen. It exerts bactericidal action against H.pylori which is accepted to be the causative factor in chronic gastritis and duodenal ulcer.
Absorption: Slightly absorbed (oral); increased absorption with increased gastric pH.
Distribution: Throughout body tissues, bones (absorbed bismuth).
Metabolism: Poorly soluble bismuth compounds are mostly converted to insoluble bismuth oxide, hydroxide and oxychloride in acidic pH of the stomach.
Excretion: Faeces (unabsorbed bismuth); urine (absorbed bismuth); 5 days (plasma half-life).
Store below 25°C.
MIMS Class
Antacids, Antireflux Agents & Antiulcerants
Disclaimer: This information is independently developed by MIMS based on Bismuth subcitrate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Trymo
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in